Abstract: The present disclosure relates to tumor-targeted split IL2 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.

Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to tumor-targeted split IL12 receptor agonists with improved therapeutic profiles.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Abstract: A storage system includes: a first storage pool; a second storage pool; a third storage pool; and a scheduling node, configured to: when a hotspot occurs in the first storage pool or the third storage pool, migrate, to the second storage pool, a part of storage volumes in the storage pool in which the hotspot occurs.

Abstract: The present disclosure relates to IL18 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a PD1 inhibitor (e.g., an anti-PD1 antibody). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.

Abstract: The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a TAAxCD3 bispecific antibody. The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.

Abstract: The present disclosure relates to IL 12 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: The present disclosure provides interferon (IFN) receptor antagonists. IFN receptor antagonists disclosed herein comprise an anchoring moiety, an IFN masking moiety, an IFN moiety, and a separator moiety, e.g., a targeting moiety that recognizes an antigen associated with cells expressing Type 1 interferon receptors and anchors the IFN receptor antagonist to such cells. The disclosure further provides pharmaceutical compositions comprising the IFN receptor antagonists, and methods of use of the IFN receptor antagonists in IFN signaling inhibition, including treatment methods. Also disclosed are nucleic acids encoding the IFN receptor antagonists, recombinant cells that express the IFN receptor antagonists, and methods of producing the IFN receptor antagonists.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to methods of increasing the efficacy of adoptive cell therapy (ACT) and methods of treating cancer, wherein the methods include administering to a subject with cancer in need thereof a combination therapy comprising a therapeutically effective amount of an ACT (e.g., an immune cell comprising a modified T cell receptor (TCR) against a tumor-associated antigen (TAA), or a chimeric antigen receptor (CAR) against a TAA) and a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival, as compared to a subject administered the ACT as monotherapy or the ACT in combination with a non-targeted immunocytokine.

Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.